Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
Portfolio Pulse from The Dales Report
Numinus Wellness Inc. (OTC:NUMIF) has partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS) to conduct a Phase 1 clinical study on MDMA-assisted therapy. The trial aims to provide practitioners with unique experiential opportunities, pending approval of their Clinical Trial Application (CTA) by Health Canada.
June 16, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Numinus Wellness partners with MAPS for a Phase 1 clinical study on MDMA-assisted therapy, which could position the company as a leader in the field if the trial is successful.
The partnership with MAPS for the Phase 1 clinical study on MDMA-assisted therapy could position Numinus Wellness as a leader in the field if the trial is successful. This would likely have a positive impact on the company's stock price in the short term, as investors may see the potential for growth in the emerging psychedelic therapy market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100